Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Recently, Beijing Huasu Pharmaceutical Co., Ltd. (Beijing Huasu), a subsidiary of the company, received the “Drug Registration Certificate” approved and issued by the State Drug Administration and learned that the “oxycodone hydrochloride sustained-release tablets” (specification: 40mg) developed by Beijing Huasu have passed the drug registration review and approval.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.